While ASCO is calling to update the 340B drug discount program, hospitals that serve economically diverse populations make a case for the program: "Because of 340B, we don't have to turn patients away when they can't pay."
David Peace, MD, has worked at the University of Illinois at Chicago in the Division of Hematology/Oncology for close to two decades, treating a socioeconomic and ethnically diverse population of cancer patients, two thirds of whom lack adequate health insurance.
The main reason that Dr Peace is able to care for so many insured and underinsured patients is because his hospital participates in a drug discount government program, known as the 340B Drug Pricing Program, which provides eligible entities with steep reductions on outpatient prescription drugs.
"Managing a diverse population is a challenge to begin with, and when you add on financial issues that often prevail in these families it becomes even more of a challenge," said Dr Peace. "But because of 340B, we don't have to turn patients away when they can't pay."
Link to the Medscape article: http://bit.ly/15QZA6c
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen